Enlivex Therapeutics (NASDAQ:ENLV) Releases Earnings Results, Beats Estimates By $12.88 EPS

Key Points

• Enlivex reported $12.85 EPS for the quarter, beating the consensus estimate of ($0.03) by $12.88.
• Shares opened at $1.10 and were down about 0.9%, with a market cap of $261.12 million and a 12‑month trading range of $0.66–$2.10.
• Analyst sentiment is mixed—one Buy, one Hold and one Sell—with a consensus target price of $13.00 (HC Wainwright raised its target to $13.00 while Weiss Ratings reiterated a sell).

Enlivex Therapeutics (NASDAQ:ENLV - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $12.85 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $12.88, FiscalAI reports.

Enlivex Therapeutics Stock Down 0.9%

Shares of ENLV opened at $1.10 on Wednesday. The company has a market cap of $261.12 million, a price-to-earnings ratio of -2.00 and a beta of 1.55. Enlivex Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.10. The company has a 50 day moving average of $1.09 and a two-hundred day moving average of $1.02.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on ENLV shares. Wall Street Zen raised Enlivex Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. HC Wainwright lifted their target price on Enlivex Therapeutics from $7.00 to $13.00 and gave the company a "buy" rating in a research report on Monday, January 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $13.00.

Institutional Trading of Enlivex Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in Enlivex Therapeutics during the 4th quarter worth $33,000. Invesco Ltd. purchased a new stake in Enlivex Therapeutics in the fourth quarter valued at about $43,000. XTX Topco Ltd boosted its holdings in Enlivex Therapeutics by 44.8% in the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company's stock worth $43,000 after acquiring an additional 19,132 shares in the last quarter. Jane Street Group LLC boosted its holdings in Enlivex Therapeutics by 244.1% in the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company's stock worth $52,000 after acquiring an additional 52,553 shares in the last quarter. Finally, Susquehanna International Group LLP purchased a new stake in shares of Enlivex Therapeutics during the third quarter worth about $57,000. Hedge funds and other institutional investors own 1.02% of the company's stock.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company's lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.